$ELV

PERU RAMIRO G purchased $366K of ELV

PERU RAMIRO G purchased 1,000 shares of Elevance Health, Inc. (ELV) at $366.05 ($0.37M total) on 2026-07-17.

Original reporting
SEC EDGAR · PERU RAMIRO G
Published Jul 17, 2026, 7:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 17, 2026, 7:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ELV
Bullish
medium confidence
Mentioned
$ELV
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ELVBullishLow
01

Why it matters

The newest concrete fact is the director’s open-market purchase of 1,000 shares at a stated price on 2026-07-17.

02

Market read

Traders may monitor for follow-on insider activity, but this single Form 4 purchase is unlikely to move the stock materially by itself.

03

What to watch

The article does not state whether the purchase was part of a broader pattern, nor does it provide context on prior holdings changes beyond the post-transaction share count.

Relevance 5/10Novelty 5/10Timing: filed same day, 2026-07-17 (after-hours/late session disclosure)

Background

The article is an SEC Form 4 insider transaction disclosure for Elevance Health, Inc.

Company-level read

Ticker impact

$ELVBullishMedium confidence
Context

Elevance Health director PERU RAMIRO G bought 1,000 shares on 2026-07-17 at $366.05, totaling $366,050, per Form 4.

Expected impact

Likely limited near-term price impact; any effect is sentiment-driven and typically fades.

Evidence & confidence

The filing is a primary-source Form 4, but the transaction size and lack of 10b5-1 pre-arrangement details reduce signal strength for trading decisions.

Market effects

No direct sector read-through; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Insider open-market buys can be driven by diversification, liquidity needs, or non-informational motives, so the signal may be weak.

Key entities

  • Elevance Health, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • PERU RAMIRO G

    Director who purchased 1,000 shares on 2026-07-17.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ELVMed

Cantor Fitzgerald keeps Elevance stock rating on Medicare concerns

Cantor Fitzgerald maintained an Overweight rating and $450 price target for Elevance Health (ELV) despite a decline in its 2027 Medicare Stars ratings. The firm expects pressure on the stock due to concerns around Medicare Advantage management. Elevance reaffirmed its 2026 earnings guidance, projecting at least $20.10 per diluted share. Analysts have mixed views, with Guggenheim raising its target to $455 and RBC lowering it to $424.

$CNCHigh

ACA fraud crackdown threatens health insurer profits in 2026

Vice President JD Vance announced 760,000 ACA enrollees were dropped due to fraud, with 400,000 under review. Insurers like Centene, Molina, Elevance, and UnitedHealth saw stock declines. Experts warn of squeezed margins in 2026-2027 due to a less healthy risk pool. Premium rates for 2027 are locked, and insurers may push for higher 2028 rates. Brokers, who drive 75% of sign-ups, face new restrictions and potential reputational damage.